RNA241220C18000
- 21.55
- 0.000.00%
Avidity Biosciences Newsroom
Avidity Biosciences (RNA) Receives a Buy From TD Cowen
Avidity Biosciences: Advancing Clinical Programs With Strategic Focus and Growth Potential
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Avidity Biosciences to Participate in Upcoming Investor Conference
RBC Initiates Avidity Biosciences at Outperform, Speculative Risk With $67 Price Target
RBC Capital Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $67
Express News | Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Insider Sale: Chief Human Resources Officer of $RNA (RNA) Sells 25,000 Shares
RNA Stock Hits Record High on Entering the Cardiac Disease Space
Avidity Biosciences: Expanding Horizons in Precision Cardiology With New Genetic Targets
Avidity Biosciences Price Target Maintained With a $65.00/Share by Chardan Capital
Avidity Biosciences Is Maintained at Buy by Chardan Capital
Avidity Biosciences Jumps 16%; Reaches All-time High
Express News | Avidity Biosciences Shares Are Trading Higher. Needham Reiterated a Buy Rating on the Stock
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $78
TD Cowen Reaffirms Their Buy Rating on Avidity Biosciences (RNA)
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $51 to $65
Avidity Biosciences (RNA) Gets a Buy From Barclays
Avidity Biosciences Analyst Ratings